Navigation Links
Pharmasset to Webcast an Investor Event from the AASLD Meeting
Date:11/1/2009

PRINCETON, N.J., Nov. 1 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) today announced that it will webcast an investor event from the American Association for the Study of Liver Diseases (AASLD) on Monday, November 2, 2009 starting at 7:00pm ET. During this webcast, management will review Pharmasset's progress on the programs that are the subject of presentations at AASLD.

To access a simultaneous webcast of this event via the internet, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm . Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast. The following abstracts are available on the AASLD website (AASLD.org).

PSI-7851

Late Breaker Abstract 17

"Antiviral Activity, Pharmacokinetics, Safety, and Tolerability of PSI-7851, a Novel Nucleotide Polymerase Inhibitor for HCV, Following Single and 3 Day Multiple Ascending Oral Doses in Healthy Volunteers and Patients with Chronic HCV Infection" will be presented in a late breaker poster session on Monday November 2nd at 8am ET. Authors of the study are M. Rodriguez-Torres; E. Lawitz; S. Flach; J. M. Denning; E. Albanis; W. Symonds; M. M. Berrey.

RG7128/INFORM-1

Abstract 1585

"Combination Therapy with Nucleoside Polymerase R7128 and Protease R7227/ITMN-191 Inhibitors in Genotype 1 HCV Infected Patients: Interim Resistance Analysis of INFORM-1 Cohorts" will be presented in a poster session on Tuesday November 3rd at 8am ET. Authors of the study are A
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Pharmasset to Present at the UBS Global Life Sciences Conference on Monday, September 24th
3. Pharmasset Accesses up to $30 Million of Working Capital
4. Pharmasset to Present at Three Investor Conferences in November 2007
5. Pharmasset Appoints Michael Rogers as Chief Development Officer
6. Pharmasset Reports Fiscal Year End 2007 Financial Results
7. Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th
8. Pharmasset to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th
9. Pharmasset to Present at Cowen & Companys Health Care Conference on Tuesday, March 18th
10. Pharmasset Appoints Herbert J. Conrad as a Director
11. Pharmasset Receives $10 Million of Working Capital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... DTS Language Services, Inc . is pleased to announce ... organizations who need document translations. Clients will now have ... in advance with a selection of nearly 50 life science ... critical factor in clinical and scientific fields, and decrease the ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. ... Road, Warrington, Pa. , Details: The Hepatitis B ... a cure for hepatitis B and improving the quality of ... Ball on Friday, April 11 at Warrington Country Club in ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
(Date:1/14/2014)... 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a ... innovative therapies addressing major unmet medical needs using ... Notice of Allowance from the United States Patent ... compounds (sd-rxRNA®), for the treatment of fibrosis. The ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... cells, called photoreceptors, could hold the key to stopping ... diseases, Yale School of Medicine researchers report in the ... Several blinding disorders are known to cause ... comparative medicine and ophthalmology at Yale School of Medicine, ...
... , PHOENIX, Nov. 16 NutraCea (OTC: ... research and technology, announced today that Henk Hoogenkamp, a world ... meat processing industries, has agreed to act as an Executive ... results of research and development in various applications to further ...
... , BOSTON, Nov. 16 Hollis-Eden Pharmaceuticals, ... of its ongoing Phase I/II clinical trial with Apoptone® ... cancer or CRPC). Presented at the Molecular ... the AACR, NCI and EORTC, the poster is titled: ...
Cached Biology Technology:Finding a protective mechanism for retinal cells could save sight 2Henk Hoogenkamp, Accomplished Author and Food Ingredient Scientist, Joins NutraCea as Executive Advisor on the Utilization of Stabilized Rice Bran in Food Ingredient Applications 2Henk Hoogenkamp, Accomplished Author and Food Ingredient Scientist, Joins NutraCea as Executive Advisor on the Utilization of Stabilized Rice Bran in Food Ingredient Applications 3Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Therapeutics Conference 2Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Therapeutics Conference 3Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Therapeutics Conference 4
(Date:4/20/2014)... 2014 -- Using corn crop residue to make ethanol ... more greenhouse gases than gasoline, according to a study ... . , The findings by a University of Nebraska-Lincoln ... can be used to meet federal mandates to ramp ... Corn stover -- the stalks, leaves and cobs in ...
(Date:4/18/2014)... researchers have published soil organic carbon sequestration rates. ... organic carbon can be sequestered by simply switching from ... there is a growing body of research with evidence ... cover crops, small grains, and forages may not be ... , "Some studies have shown that both moldboard and ...
(Date:4/18/2014)... team of researchers led by a University of California, ... a $7.5 million Department of Defense grant to uncover ... foundations for the predictable design of light-weight, tough and ... structures from plants and animals, including the mantis shrimp, ... systems have constructed over millions of years and coming ...
Breaking Biology News(10 mins):Study casts doubt on climate benefit of biofuels from corn residue 2Study casts doubt on climate benefit of biofuels from corn residue 3Researchers question published no-till soil organic carbon sequestration rates 2Researchers question published no-till soil organic carbon sequestration rates 3Researchers question published no-till soil organic carbon sequestration rates 4Mantis shrimp, toucan and trilobite, oh my 2Mantis shrimp, toucan and trilobite, oh my 3
... in the June issue of American Naturalist, Erika J. ... and Michael J. Donoghue (Yale University) explore how leafy, ... "The cactus form is often heralded as a striking ... in plants," write the authors. "A succulent, long-lived photosynthetic ...
... researcher in Washington, D.C., has been working toward tracking ... hepatitis C. , Dr. Maria Sjogren, a retired Army ... in treating liver disease, has enrolled 90 active-duty servicemembers ... Center. The virus, which affects the U.S. military at ...
... Max Planck scientists have identified a new strategy which ... was carried out by Prof. Jonathon Howard and Stefan ... Biology and Genetics in Dresden. The motor protein MCAK ... end of microtubules where it disassembles them. This is ...
Cached Biology News:Researcher studies, treats military with 'silent disease' 2Researcher studies, treats military with 'silent disease' 3Researcher studies, treats military with 'silent disease' 4
... Idaho Technologys R.A.P.I.D. System (Ruggedized Advanced ... real-time, PCR thermocycler designed for field ... environments. In addition to its ruggedness, ... sensitivity and specify as the LightCycler ...
... ES Cell Characterization Kit consists of two ... as well as four ES cell-specific antibodies ... • Stem cells have become the subject ... their therapeutic potential and because they raise ...
... Library Panels were designed for full-length gene ... PCRs to identify the desired cDNA clone. ... a 96-well "Master Plate," where each well ... identified the positive well(s) by gel electrophoresis ...
... Note: Evaluated for its amino acid acceptor activity ... acids Ala, Asp, Gly, Ile, Lys, Pro, Thr, ... Preparation Unit Definition: One unit will yield an ... of water (1 cm light path). ...
Biology Products: